Ibandronate Injection

  • Bone disorders

Ibandronate Injection Generic Name & Formulations

General Description

Ibandronate (as sodium) 3mg/3mL; soln for IV inj.

Pharmacological Class


See Also

How Supplied

Blister pack—3; Inj—contact supplier

Ibandronate Injection Indications


Prevention and treatment of postmenopausal osteoporosis.

Limitations of Use

Optimal duration of use has not been determined. For patients at low-risk for fracture: consider drug discontinuation after 3–5yrs.

Ibandronate Injection Dosage and Administration


Must be given by healthcare professional. Give as IV bolus inj over 15–30secs. 3mg every 3 months; if dose is missed, give as soon as possible, then every 3 months from the date of last inj.


Not established.

Ibandronate Injection Contraindications


Hypocalcemia. Tabs: Esophagus abnormalities which delay esophageal emptying (eg, stricture, achalasia). Inability to stand or sit upright for at least 60mins.

Ibandronate Injection Boxed Warnings

Not Applicable

Ibandronate Injection Warnings/Precautions


Active upper GI disease; discontinue and reevaluate if signs/symptoms of esophageal reaction occur. Severe renal impairment (CrCl <30mL/min): not recommended. Correct preexisting hypocalcemia, other mineral or bone disturbances before starting. Risk of osteonecrosis of the jaw; consider discontinuing therapy during invasive dental procedures (eg, tooth extraction, implants, surgery). History of bisphosphonate exposure: evaluate for atypical fractures if thigh/groin pain develops; consider withholding therapy until risk/benefit assessment. Ensure adequate Vit. D and calcium intake. Reevaluate periodically. Inj: check renal function before each dose. Pregnancy. Nursing mothers.

Ibandronate Injection Pharmacokinetics

See Literature

Ibandronate Injection Interactions


Calcium, aluminum, magnesium, other multivalent cations reduce absorption (separate dosing by at least 60mins). Caution with aspirin, NSAIDs, other GI irritants. May interfere with bone-imaging agents. Inj: concomitant nephrotoxic agents; monitor for renal toxicity.

Ibandronate Injection Adverse Reactions

Adverse Reactions

Back pain, dyspepsia, pain in extremity, diarrhea, headache, myalgia; musculoskeletal pain (discontinue if severe), esophagitis, esophageal or gastric ulcer, jaw osteonecrosis, atypical femur fractures. Inj: inj site reactions, flu-like syndrome, anaphylaxis.

Ibandronate Injection Clinical Trials

See Literature

Ibandronate Injection Note


Formerly known under the brand name Boniva.

Ibandronate Injection Patient Counseling

See Literature